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Cyclooxygenase-2 (COX-2) enzyme has been involved in the tumorigenesis and in the progression of colorectal cancer (CRC).
The use of traditional nonsteroidal anti-inﬂammatory drugs (NSAIDs) or selective COX-2 inhibitors has been proposed for the
prevention and the treatment of this relevant neoplastic disease. In the light of an innovative alternative to these pharmacological
approaches, we review here the possible strategies to achieve a strong and selective inhibition of COX-2 enzyme by using the
mechanism of RNA Interference (RNAi) targeted against its mRNA. Anti-COX-2 siRNA molecules (siCOX-2) can be generated
in CRC cells from short hairpin RNA (shRNA) precursors, delivered in vitro by a retroviral expression system, and induce a
signiﬁcant and stable silencing of overexpressed COX-2 in human colon cancer cells. As a safer alternative to viral approach,
nonpathogenic bacteria (E. coli) can be engineered to invade eukaryotic cells and to generate siCOX-2 molecules in cancer cells.
Moreover, the involvement of miRNAs in COX-2 posttranscriptional regulation opens up the possibility to exploit an endogenous
silencing mechanism to knockdown overexpressed COX-2. Thus, these recent strategies disclose new challenging perspectives for
the development of clinically compatible siRNA or miRNA capable of selectively inhibiting COX-2 enzyme.
1.Introduction
1.1. COX-2 and Cancer. Several studies have supported the
involvement of prostanoids in the pathogenesis of cancer. In
vitro studies have demonstrated that growth factors, tumor
promoters, and oncogenes induce prostanoids synthesis [1].
In vivo, the metabolism of arachidonic acid, via the COX
pathway, has been found to be enhanced in various human
t u m o r sa n di ti sn o ww i d e l ya c c e p t e dt h a tt h i si sd u et o
the induction of COX-2 enzyme [2]. A number of theories
have been proposed to explain the role of tumor-derived
prostanoids in promotion of angiogenesis, induction of
tumor cell proliferation, suppression of immune response,
and protection against apoptosis [3–5]. The expression of
COX-1 and -2 in tumor tissues biopsies collected from
various cancershasbeenanalyzed.Inparticular, earlystudies
by Eberhart et al. [6] and Sano et al. [7] showed that
COX-2 is overexpressed in 80% of colorectal cancer tissues.
In these transformed tissues, COX-2 enzyme results to be
overexpressed in epithelial cells, inﬂammatory cells, as well
as in stromal cells. In contrast, COX-2 expression is very low
in adjacent normal tissues. COX-1 isoenzyme is expressed
at the same basal level in both normal and tumor tissues.
These ﬁndings have been conﬁrmed analyzing many tumors
including pancreas, skin, gastric, bladder, lung, head, and
neck cancers [8], suggesting that COX-2, but not COX-1,
mayplayapivotalroleintumorformationandgrowth.More
recent studies conﬁrmed that the upregulated expression
of COX-2, probably induced by carcinogenic stimuli or
other tumor promoters, is an important contributor to
tumorigenesis [9]. It is now clear that the tumorigenesis
involves COX-2 overexpression in most cases, even if the
molecular mechanisms responsible for this overexpression
have not been completely understood. Diﬀerent in vitro
studies support the idea that COX-2 overexpression inhibits
apoptosis and promotes tumor angiogenesis [2, 9, 10]. In
fact, COX-2 overexpression in tissues seems to be crucial to
favor the development of new vasculature supporting tumor
growth and metastatization.
Following the development of animal models of tumori-
genesis it has been demonstrated that NSAIDs strongly
inhibit colon and breast tumors in rodents [11], further2 Journal of Biomedicine and Biotechnology
suggesting that products of the COX pathways may par-
ticipate in carcinogen-induced tumorigenesis. The cancer
chemopreventive activity of NSAIDs has been supported
by epidemiological studies performed on humans taking
aspirin and other NSAIDs on a regular basis. These studies
demonstrate that incidence of various cancers, including
colon, intestinal, gastric, breast, and bladder cancers, is
reduced up to 40–50% [8]. Aspirin, which is a COX-1 and
COX-2 inhibitor, has been shown to be moderately eﬀective
in preventing sporadic colorectal adenomas in patients with
a familiar history of these tumors [12]. Epidemiological
studies suggest that aspirin, especially if used in high doses
f o rm o r et h a n1 0y e a r s ,i se ﬀective in reducing the incidence
of colonic adenoma and CRC, even if careful consideration
should be devoted to the possible harms of such a practice
[13]. Celecoxib and rofecoxib, COX-2 selective drugs, have
also been shown to reduce adenomas’ incidence and to
induce tumor regression in patients with familial polyposis
[14, 15]. Duodenal adenomas, which are otherwise untreat-
able, show some reduction by treatment with celecoxib [14].
The antineoplastic activity of NSAIDs has been extensively
reviewed elsewhere [16]. Recent studies demonstrate that
COX-2 blocking agents have strong potential for the chemo-
prevention of breast, prostate, colon, and lung cancers [17]
and that multifactorial molecular events may be involved
in such activity. Among them, the induction of apoptosis
appears to be an essential factor in explaining the ability of
these drugs to cause tumor regression [18]. Clinical trials
have conﬁrmed that NSAIDs, especially selective COX-2
inhibitors (coxibs), eﬀectively prevent colorectal adenoma
formation. On the basis of available data, COX-2 inhibitors
are likely to be highly eﬀective cancer chemopreventive
agents. Yet, they also have substantial side-eﬀects that
currentlylimittheirroutineuse[19].Theplacebo-controlled
trials APC (Adenoma Prevention with Celecoxib), PreSAP
(Prevention of Spontaneous Adenomatous Polyps), and
APPROVe (Adenomatous Polyp Prevention on Vioxx) of
celecoxib and rofecoxib were stopped early because interim
safety results indicated an increased cardiovascular risk in
participants receiving active medication [20–22]. Since the
COX-2 isoform is one of the major sources of endothelium-
derived prostacyclin (PGI2) under physiological conditions,
it has been hypothesized that selective blockade of COX-2
mightimpairendothelialfunctionandpredisposepatientsto
cardiovascular disease [23, 24]. Moreover, the cardiovascular
toxicity of rofecoxib could be increased by its capability
to directly inhibit prostacyclin synthase activity, as demon-
s t r a t e db yo u rg r o u p[ 25].
2. COX-2 SilencingMediatedbysiRNA
In the last decade, RNA Interference (RNAi) has rapidly
become an innovative and elective tool for studying genes
function. Based on the works of Fire and Mello in 1998 on
Caenorhabditis elegans [26], Hammond et al. and Zamore
et al. in 2000 on Drosophila cells extracts [27, 28], and
Tuschl and colleagues on mammalian cells [29], small
interfering RNAs (siRNAs), 21–23nt dsRNAs molecules
with 2-3nt overhangs on their 3 -ends, were deﬁned as
the eﬀectors of the RNAi pathway. They are capable of
binding to homologous target mRNAs leading to cleavage
of the transcript near the centre of the pairing sequence.
To date, the RNAi pathway has been almost totally deﬁned.
Synthetic mature siRNAs can be transfected into cells or
generated both in transient and stable manner from longer
dsRNA precursors or from ssRNA molecules containing a
complementary dsRNA domain called short hairpin RNAs
(shRNAs).ActivesiRNAsareprocessedintocytoplasmbythe
RNase III endoribonuclease Dicer [30] and mRNA cleavage
is mediated by a ribonucleoprotein complex, known as the
RNA-induced silencing complex (RISC), after incorporation
of the “guide” strand of the siRNA duplex. RISC contains
one of the eight known Argonaute proteins in humans,
Ago2, characterized by an RNA-binding domain (PAZ
domain) and an RNase H-like domain (PIWI domain)
[31].
RNAi technology has been successfully used to silence
COX-2 protein in diﬀerent in vitro models (Table 1).
The use of innovative RNAi-based techniques has enabled
researchers to better study the molecular and phenotypical
loss of function of Cox-2 gene by performing experiments
based on a strong COX-2 silencing deprived of aspeciﬁc
eﬀects. In 2003, Denkert and collaborators tested for the
ﬁrst time the eﬃcacy of an anti-COX-2 siRNA (siCOX-2)
on OVCAR-3 cells derived from human ovarian carcinoma
[32]. A comparison with the COX-2 inhibitory drug NS-398
highlighted a diﬀerent eﬀect of siCOX-2 due to its highly
speciﬁc mechanism of action. Even though COX-2 protein
levels resulted signiﬁcantly reduced in both cases after Il-1β
stimulation, only NS-398 treatment induced a G0/G1 cell
cycle arrest in OVCAR-3 cells. This eﬀect could be due to
the action of NS-398 on other cellular targets involved in cell
proliferation, conﬁrming the lack of speciﬁcity of NSAIDs
in COX-2 blocking. Recent works by Charames and Bapat
[33] and Kobayashi et al. [34] showed an eﬃcient COX-2
knockdown mediated by siRNAs in HT-29 human colon
cancer cells and bovine Cumulus-Granulosa (CG) cells,
respectively. Based on their results on cell apoptosis [33],
Charames and Bapat have conﬁrmed a COX-2-independent
mechanism of action of NSAIDs, previously described by
severalresearchgroups[35–38].Fromthesestudies,itresults
clear that RNAi, compared with NSAIDs, is a more powerful
and selective tool for studying in vitro the functional role of
COX-2.
However, RNAi-mediated COX-2 silencing proved to be
highly eﬀective using anti-COX-2 shRNAs (shCOX-2). In
2006, our group published a paper in which an in vitro strat-
egy to stably knockdown COX-2 in colon cancer cells (HT-
29) was described [39]. Firstly, we tested diﬀerent sequences
of siCOX-2 in HUVE (human umbilical vein endothelial)
cells. Among these, one siCOX-2 resulted to be more eﬀec-
tive in silencing COX-2 protein after PMA transcriptional
induction and led to a reduction of PGI2 levels and to
the impairment of the ability of HUVE cells to organize
capillary-like tubular structures in 3D gel. Furthermore,
the active siCOX-2 sequence (5 -aactgctcaacaccggaattt-3 )
was used to design a shCOX-2 in order to silence COX-
2 in HT-29 colon cancer cells in a long-lasting manner.Journal of Biomedicine and Biotechnology 3
Table 1: COX-2 silencing mediated by RNAi.
Study Model RNAi-silencing Eﬀects Ref
Denkert et al.
2003
OVCAR-3 cells
(human ovarian
carcinoma)
siCOX-2 (short term
expression)
- COX-2 protein silencing
- Reduction of PGE2 levels [32]
-N oe ﬀects on cell proliferation
Strillacci et al.
2006
HUVECs (human
umbilical vein
endothelial cells)
siCOX-2 (short term
expression)
- COX-2 protein silencing
- Reduction of 6-keto-PGF2α levels
- Reduction of capillary-like tubular [39]
structures on 3D collagen gel
-N oe ﬀects on interferon system
Strillacci et al.
2006
HT-29 cells (human
colon carcinoma)
shCOX-2 (stable
expression)
- COX-2 protein and mRNA silencing
- Reduction of PGE2 levels
-N oe ﬀects on interferon system [39]
-N oe ﬀects on cell proliferation
- Impairment of malignant behavior
Charames and
Bapat 2006
HT-29 cells (human
colon carcinoma)
siCOX-2 (short term
expression)
- COX-2 protein and mRNA silencing [33]
-N oe ﬀects on cell apoptosis
Kobayashi et al.
2007
CG cells (bovine
Cumulus Granulosa)
siCOX-2 (short-term
expression)
- COX-2 mRNA silencing [34]
- Reduction of PGF2α levels
Wang et al. 2008 Hep-2 cells (human
laryngeal carcinoma)
shCOX-2 (stable
expression)
- COX-2 protein and mRNA silencing
- Inhibition of proliferation
- Impairment of malignant behavior [40]
- Inhibition of in vivo growth
- Enhanced chemosensitivity in vitro and in vivo
Sansone et al.
2008
HT-29 cells (human
colon carcinoma)
shCOX-2 (stable
expression)
- COX-2 protein and mRNA silencing
- Inhibition of Erk phosphorilation
- Inhibition of CA-IX expression
- Inhibition of cell invasion [41]
- Inhibition of MMP-2 activation
-N oe ﬀects on cell death
- Inhibition of hypoxic survival
The stable expression of shCOX-2 in HT-29 (HT-29shCOX-2)
induced a strong COX-2 silencing at protein, mRNA, and
product (PGE2) levels, devoid of toxic eﬀects (no activation
of the interferon system). Phenotypically, COX-2 stable
knockdown did not aﬀect cell proliferation and cell cycle
distribution but it strongly impaired the malignant behavior
of HT-29 colon cancer cells in vitro. In fact, the invasiveness
of HT-29shCOX-2 cells was reduced, as well as their ability to
form colonies in soft-agar. This novel approach for COX-
2 silencing is very promising and its eﬀectiveness has been
further conﬁrmed by the work of Wang and collaborators
[40] who performed a stable silencing of COX-2 protein
mediated by shRNA in human laryngeal carcinoma Hep-2
cells. In this model, COX-2 silencing induced a reduction of
proliferation and invasiveness, coupled with increased apop-
tosis. Moreover, a reduced tumorigenesis was demonstrated
with Hep-2shCOX-2 xenografts in nude mice. Finally, our HT-
29shCOX-2 model was successfully used to better elucidate
the role of COX-2 in the hypoxic environment of colon
cancer. In particular, we recently demonstrated an important
interplay between COX-2 and carbonic anhydrase-IX (CA-
IX, an enzyme controlling cellular pH) that promotes the
hypoxic survival and invasiveness of colon cancer cells
[41].
3. Transkingdom RNAi and
Enhanced COX-2 Silencing
Several years ago, it was demonstrated that systemic gene
silencing occurs in the nematode Caenorhabditis elegans
after ingestion of Escherichia coli engineered to produce
interfering RNAs, thus suggesting that RNAi-mediated gene
silencing between species or kingdoms might be possible
[42, 43]. Bacteria engineered to produce shRNAs can induce
transkingdom RNAi (tkRNAi) in vitro and in vivo also in
mammalian systems. A successful transfer of shRNAs into
mammalian cells can be obtained using nonpathogenic E.
coli transformed with a plasmid containing an expression4 Journal of Biomedicine and Biotechnology
cassette for shRNA and Inv/HlyA genes. In particular, Inv
and HlyA encode the two bacterial factors (invasin and
listeriolysin-O, resp.) responsible for the eﬃcient transfer
of shRNA from bacteria to mammalian cells. In 2006,
Xiang et al. applied for the ﬁrst time this new technology
to silence β-1 catenin gene (CTNNB1)i nh u m a nc e l l s
[44]. Firstly, they assessed the eﬃcacy of tkRNAi against
β-catenin in vitro on SW-480 colon carcinoma cell line.
Then, β-catenin silencing tkRNAi-mediated was achieved
also in vivo, in normal mouse intestinal epithelium and in
xenografts of human colon cancer cells in mice. Based on
theseresults,tkRNAiinmammalscouldrepresentapowerful
and innovative strategy for functional genomics studies and
for the development of clinically compatible RNAi-based
therapies. In 2007, Cequent Pharmaceuticals (Cambridge,
MA, USA) started to develop and validate new therapies for
familial adenomatous polyposis (FAP) and CEQ501, the ﬁrst
tkRNAi-baseddrug,iscurrentlyinadvancedpreclinicaltrials
[45].
In our laboratory, we have developed a tkRNAi-based
strategy to eﬃcaciously silence COX-2 in colon cancer cells.
We tried to combine our knowledge on COX-2 knock-
down mediated by RNAi with this transkingdom strategy
(Figure 1). Infection of HCA-7 colon cancer cells with
tkColi
shCOX-2 determined a signiﬁcant reduction of COX-
2 mRNA and protein levels in this colon cancer cell lines
(Figure 2). Moreover, COX-2 silencing mediated by tkRNAi
induced a signiﬁcant decrease in cell invasiveness in HT-29
and HCA-7 cell lines (Figure 2). We consider these data to
be very promising and, as a consequence, we are trying to
improve this strategy in order to obtain an enhanced and
highly speciﬁc COX-2 silencing in colon cancer cells, in the
light of compatible in vivo applications.
4. PosttranscriptionalCox-2 Regulation
Mediatedby MicroRNAs
MicroRNAs (miRNAs) have been found to be strongly
implicated in the control of gene expression and it is believed
that up to 30% of human genes are regulated by miRNAs
[46]. To date, hundreds of miRNAs have been isolated in
mammalians and their sequences are listed in the oﬃcial
miRNA database (miRBase, http://microrna.sanger.ac.uk/
index.shtml)[ 47]. Mature miRNA molecules (RNA duplexes
of 19–24 nucleotides length with 2-nt overhangs in 3 -ends)
are produced by the cellular machinery after the enzymatic
cleavage of longer precursors (pri- and pre-miRNAs) [48,
49]. Following the incorporation into the RNA-induced
silencing complex (RISC), the pairing of miRNAs (as single-
strand molecules) with target mRNAs carrying a partially
complementary sequence in the 3 -untranslated region (3 -
UTR) causes the translational repression and/or degradation
of the messengers, resulting in the silencing of target genes
[50].
miRNAs can regulate cellular genes involved in prolif-
eration, in diﬀerentiation, or in apoptosis, and alterations
of their expression have been found in various human
tumors [51], including colon cancer [52]. In fact, data from
recent literature clearly show that disturbances of miRNAs
expression levels have detrimental eﬀects on cell physiology
and may be directly implicated in carcinogenic processes.
These miRNAs, whose mutation or misexpression correlates
with various human cancers, are deﬁned “oncomiRs” and
they can function as tumor suppressors or oncogenes [53].
Examples of oncomiRs are miRNAs from the miR-17-
92 family, miR-155 (overexpressed in chronic lymphocytic
leukemia,CLL),miR-106a,miR-21,miR-221,miR-372,miR-
373, and many others. MiR-15 and miR-16, let-7 family
members, miR-143, and miR-145 have been deﬁned tumor
suppressor miRNAs since they are downregulated in some
malignancies, including colon cancer [54, 55].
Many intracellular pathways contribute to the induction
of COX-2 protein expression, both at transcriptional (see
below) and post-transcriptional level. With regards to COX-
2 post-transcriptional regulation, it has been widely demon-
strated that COX-2 mRNA shows an increased stability due
to a mechanism that involves AU-rich regions in its 3 -UTR
[56]. Moreover, novel data from literature have shown a
direct link between COX-2 expression and miRNA-mediated
translational silencing (Table 2). Dey and collaborators
ﬁrstly described an inverse relationship between COX-2
and miR-101a/miR-199a expression in mice. In particular,
they have shown that low levels of miR-101a and miR-
199a associate with high COX-2 expression during mouse
embryo implantation [57] and during mouse endometrial
carcinogenesis [58]. Since COX-2 overexpression is involved
in human CRC tumorigenesis, miR-101 and/or miR-199a
could act as tumor suppressor miRNAs in CRC. This
hypothesis has been conﬁrmed in our laboratory. We
recently reported the inverse correlation between COX-
2 and miR-101 expression in colon cancer cell lines and
we demonstrated in vitro the direct inhibition of COX-2
mRNA translation mediated by miR-101. This correlation
was supported also by data collected ex vivo, in which
colon cancer tissues and liver metastases derived from CRC
patients were analyzed [59]. These ﬁndings provide a novel
molecular insight in the modulation of COX-2 at post-
transcriptional level by miR-101 and strengthen the thesis
that miRNAs are highly implicated in the control of gene
expression.AnimpairmentofmiR-101levelscouldrepresent
one of the leading causes of COX-2 overexpression in colon
cancer cells and, in our opinion, a novel CRC therapy
could be based on COX-2 silencing mediated by miR-101
molecule.
Finally, it has been shown that also miR-16 plays a role in
COX-2 mRNA destabilization and promotes its degradation
in human THP-1 monocytic cells [60].
5.Transcriptional-BasedCOX-2 Inhibition
The control of Cox-2 gene transcription can be mediated by
various transcription factors such as NF-κB[ 61], C/EBPβ
[62], CREB [63], NFAT [64], AP-1 [65], and PPAR [66],
and it has been demostrated that also HIF-1α factor
induces COX-2 overexpression in hypoxic condition [67]. A
transcriptional-based COX-2 inhibition could be developed
by using selective inhibitors of these transcriptional factors.
In particular, C/EBPβ s e e m st oh a v eap i v o t a lr o l ei nC O X - 2Journal of Biomedicine and Biotechnology 5
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Figure 1: COX-2 silencing mediated by transkingdom RNAi. The cotransformation of E. coli with both plasmids pGB2Ωinv-hly and
pSUPER.retroshCOX-2 enables bacteria to induce the transkingdom RNAi phenomenon in colon cancer cells. Following the expression of
the bacterial proteins invasin and listeriolysin-O, engineered E. coli strains are able to permeate human cells and release the plasmid DNA
content. Anti-COX-2 shRNAs are then transcribed by the cellular machinery, resulting in an eﬃcient COX-2 silencing.
Table 2: Anti-COX-2 miRNAs.
Study miRNAs Model Function Ref
Chakrabarty
et al. 2007
mmu-miR 199a∗
mmu-miR-101a mouse
- Correlate inversely with COX-2 protein
[57] during embryo implantation
- Regulate COX-2 protein expression
Daikoku et al.
2008
mmu-miR-199a∗
mmu-miR-101a mouse - Correlate inversely with COX-2 protein
[58]
in endometrial cancer cells
Strillacci et al.
2008 hsa-miR-101 homo
- Correlates inversely with COX-2 protein
[59] in colon cancer cells
- Regulates COX-2 protein expression
(translational repression)
Shanmugam
et al. 2008 hsa-miR-16 homo -P r o m o t e sC O X - 2m R N Ad e g r a d a t i o ni n
[60]
THP-1 monocytic cells
transcriptional activation by proinﬂammatory mediators
[62, 68, 69] and in cancer cells [70, 71]. Moreover, it
has been demonstrated that salicylate at pharmacological
concentration inhibits COX-2 expression (50%) by blocking
C/EBPβ phosphorylation and activation via p90 riboso-
mal S6 kinase 1/2 (RSK1/2) [72]. Based on these pieces
of evidence, Wu and colleagues have proposed that the
inhibition of RSK1/2 or C/EBPβ expression by speciﬁc
siRNAs and/or the inhibition of RSK1/2 activity by phar-
macological approaches may have therapeutic potential in
reducing COX-2 overexpression in human pathologies (e.g.,
inﬂammation, cancer) without aﬀecting the physiological
function of COX-2 enzyme. However, transcriptional-based
COX-2 inhibition could lack speciﬁcity since transcriptional
factors are involved in the control of a wide number
of genes and RSK1/2 is involved in phosphorylation of
other proteins that may have a role in cell physiology
[73].
6. Conclusion
Considering the recent literature regarding the application
of RNAi-based strategies to modulate gene expression and
the study of miRNAs-mediated COX-2 silencing, new COX-
2 selective inhibitors based on siRNA or miRNA molecules
could be developed. In particular, we suggest that anti-COX-
2 siRNAs (siCOX-2) and/or miRNAs (miR-101, miR-199a)
may represent innovative tools for COX-2 silencing, espe-
cially in CRC therapy. To date, selective COX-2 inhibitors
(coxibs) have been tested for CRC treatment but, despite the
eﬃcacy in COX-2 blockade, an increased cardiovascular risk
has been observed in chronically treated patients. In order
topreventadverseside-eﬀects,tissue-speciﬁcexpression,and
targeting of siCOX-2, miR-101 or miR-199a could lead to
a strong and highly speciﬁc COX-2 silencing deprived of
secondary eﬀects on other targets (e.g., PGI2 synthase) or
other tissues (e.g., cardiovascular system).6 Journal of Biomedicine and Biotechnology
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Figure 2: Invasive tkColi infect CRC HT-29 cells and promote high COX-2 silencing associated with a reduced invasive behavior. E. coli was
cotransformed with pGB2-Ω-inv-hly plasmid and pSUPER.retro vectors to obtain E. coli invasive strains carrying the shCOX-2 expression
vectortkColi-pSTBE(inwhichshCOX-2expressioniscontrolledbyTBEpromotercarryingTcfBindingElements).Thenegativecontrolwas
tkColi-pS-(notexpressingshCOX2butcontainingtheoriginalemptypSUPER.retrovector).GFPproteinexpression(a)wasusedtoevaluate
the eﬃciency of tkColi infection of HT-29 cells (bar = 30μm). 72 hours after the infection, the eﬃciency of infection was higher than 75%.
The expressions of COX-2 protein and COX-2mRNA were analyzed in HT-29 cells, 72 hours after tkColi infection, by Western blot and real-
time PCR (c). COX-2 protein and COX-2 mRNA expressions were normalized against β-actin protein and GUSB (β-glucuronidase) mRNA
levels, respectively. Relative expression of COX-2 protein and COX-2 mRNA refers to tkColi-pS-infected sample. The invasive behavior
of tkColi infected CRC HT-29 cells was evaluated by using Boyden chambers and 8-μm polycarbonate membranes coated with Matrigel.
Samples were tested in the absence (dark bars) and in the presence (light bars) of PMA 40nM. Relative invasion index refers to HT-29 cells
infected with tkColi-pS-, not treated with PMA. Data reported in (b)–(d) represent the mean ± SEM of three independent experiments;
∗P <. 01.
Many research groups and companies are trying to
develop completely new strategies based on miRNAs for
an in vivo therapeutic application. Even though miRNAs
expression patterns in human cells are not completely
understood, the possibility of their modulation represents
an exciting challenge for targeting COX-2 activity in vivo.
However, clinical trials based on therapeutic small RNAs
are still far. The eﬃciency of siRNAs and miRNAs delivery
into target cells, using a nonviral delivery system, is still
inadequate. To overcome these barriers, a wide number
of modiﬁed small RNAs and functional carriers have been
developed as an alternative strategy to viral vectors which
cannotbeconsideredsafevehiclesfortherapeuticapplication
in humans. In vivo, the eﬃcacy of delivered siRNAs depends
on diﬀerent factors such as pharmacokinetics, resistance to
exonuclease digestion, or maintenance of duplexes integrity.
Locked nucleic acids (LNAs), siRNAs with a partial phos-
phorothioate backbone, or siRNAs with the inclusion of
2 -O-methyl dinucleotides at the 3 -end of the antisense
strand have shown enhanced stability. Improvements on
the pharmacodynamics of siRNAs were obtained as well,
using conjugated-siRNAs (e.g., cholesterol-conjugated) [74]Journal of Biomedicine and Biotechnology 7
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Figure 3: The diﬀerent strategies for COX-2 blockade. (a) COX-2 selective NSAIDs (e.g., celecoxib, rofecoxib, etoricoxib) represent to
date the only drugs marketed for COX-2 selective inhibition, even if rofecoxib has been withdrawn due to its toxicity; (b) inhibitors of
transcriptional factors expression and/or activity (e.g., C/EBPβ transactivator) may block COX-2 overexpression associated to inﬂammation
or cancer; (c) anti-COX-2 siRNAs (siCOX-2) or miRNAs (e.g., miR-101) with structural modiﬁcations that improve their stability may
block COX-2 expression after intravenous administration; (d) polymer- or lipid-based delivery systems protect siRNAs or miRNA from the
extracellular environment and, modifying their shell, a more selective cellular targeting can be obtained; (e) nonpathogenic bacteria (E. coli)
can be engineered in order to invade target cells and induce RNAi against COX-2 (transkingdom RNAi, tkRNAi) by releasing DNA plasmids
that express siCOX-2 or miR-101 precursors; (f) anti-COX-2 shRNA (shCOX-2) or pre-miRNA expression cassettes can be transduced into
target cells genome by the use of recombinant retroviruses, allowing a stable COX-2 silencing into mammalian cells.
or protecting siRNAs from the extracellular environment
with polymer- or lipid-based delivery systems (e.g., cationic
polyethylenimines or lipid-polyethylene glycol mixtures)
[75, 76]. Cationic liposome-mediated delivery of anti-COX-
2 siRNA was recently used in vivo [77] and resulted in an
eﬃcient downregulation of COX-2 in tumor cells. Further-
more, various types of synthetic carrier systems for small
RNAs delivery have been developed to target tumor tissues
preferentially through the blood stream, such as polyplexes
[78]. In our laboratories, biocompatible polymeric micelles
have shown to be nontoxic carriers capable to eﬃciently
deliver small RNA molecules into mammalian cells cytosol
(Benaglia M. and Spisni E, Ms. Submitted). The possibility
to modify their shell, in order to obtain a more selective
cellular targeting, has been documented by many authors
[77, 79], opening up the perspective to deliver in vivo small
RNA molecules in a speciﬁc and eﬃcient manner.
Nonpathogenic bacteria, engineered to induce tkRNAi
against COX-2 in CRC cells (tkColi
shCOX-2), could represent
an innovative and potent strategy to achieve a strong COX-
2 silencing directly in the intestinal mucosa of the patients
aﬀected by CRC, with a relatively high speciﬁcity associated
with low systemic eﬀects. Moreover, this approach directed
against other cellular targets, such as tumor necrosis factor
alpha(TNFα),couldbealsoverypromisingforthetreatment
of other inﬂammatory bowel diseases (e.g., ulcerative colitis,
Crohn’s disease).
Important remarks could be made about the use of
siRNAs instead of miRNAs for an anti-COX-2 therapeutic
application. In general, both siRNAs and miRNAs can
induce eﬀective gene silencing by a similar mechanism
of action [80] and the eﬀective delivery of their mature
molecules can be improved by using the same techniques.
However, siRNAs and miRNAs have a diﬀerent speciﬁcity in
silencing genes and they can induce a diﬀerent toxicity when
transientlyorconstitutivelyexpresseddirectlyinmammalian
cells. We cannot completely exclude that siCOX-2 could
generate oﬀ-target eﬀects in treated cells, silencing other
mRNAs that have partial complementarity [81]. Similarily,
COX-2 inhibition mediated by miR-101 or miR-199a could
interfere with the expression of other target genes [82–85].
Surely, an miR-101/199a control of COX-2 expression could
represent a more suitable approach for the treatment of
human pathologies characterized by both COX-2 overex-
pression and miR-101 downregulation (e.g., colon cancer,
endometrial serous adenocarcinoma) [59, 86]. Even though
an shRNA/siRNA-mediated gene silencing could result more
eﬀective [87], a constitutive expression of shRNAs could
lead to a lower speciﬁcity of action and a higher level of
toxicity. This may be due to the saturation of the cellular
machinery deputed to endogenous miRNAs processing and
exportation [88] causing the induction of nonsequence-
speciﬁc silencing pathway (e.g., interferon system activation)
which is not observed when using miRNAs [89, 90]. In8 Journal of Biomedicine and Biotechnology
the light of this evidence, it is likely that miRNA-based
strategies for COX-2 inhibition may be a more appropriate
alternativeforthetreatmentofhumanpathologiesassociated
toCOX-2overexpression.ThesediﬀerentstrategiesforCOX-
2 blockade are summarized in Figure 3.
Finally, since transactivators such as C/EBPβ are strongly
implicated in COX-2 induction at transcriptional level, we
suggest that inhibition of C/EBPβ expression or activity by
the use of RNAi or other molecular compounds may reduce
COX-2overexpressionassociatedtohumanpathologiessuch
as inﬂammation or colon cancer.
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